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Disability, Public health, Global Burden of Disease study, Global Campaign against HeadacheIf it were needed, more evidence of the disconcerting
under-treatment of headache disorders has come from
the Eurolight study [1]. The topic is not new. Twenty
years ago, the International and American Headache
Societies jointly voiced their dismay at the inadequacies
of health care for headache [2]. In 2006, the European
Headache Federation and World Headache Alliance
described migraine as a “forgotten epidemic” [3]. Mean-
while, in 2003, the Global Campaign against Headache
[4–6] engaged the World Health Organization (WHO)
as partner in this cause [7], embarking on a worldwide
action programme which began by assessing the magni-
tude of headache in the world [4, 8]. In 2011, WHO’s
global survey of headache disorders and resources, a
Global Campaign project, laid bare the scale and scope
of under-treated headache everywhere, and its conse-
quences [9]. WHO wrote, in a message sent inter alia to
the world’s Ministries of Health: “This first global
enquiry into these matters illuminates the worldwide
neglect of a major public-health problem, and reveals
the inadequacies of responses to it in countries through-
out the world” [9]. No words could be clearer but, to
make sure, WHO repeated the message soon after [10].
Eurolight was a cross-sectional survey of over 8000 par-
ticipants, conducted by multiple partners (scientific and
lay) in 10 European countries [11]. A considerable
strength of this study, apart from its size and geographical
scope, was the use in all countries of the same question-
naire [12], a derivative of the HARDSHIP questionnaire
already employed in many different countries, cultures
and translations [13]. Also a strength was its scope of* Correspondence: t.steiner@imperial.ac.uk
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ache (TTH) and medication-overuse headache (MOH),
the three headache disorders of major public-health
importance. This provided a broad view of headache in
Europe. The different sampling methods employed by the
countries in Eurolight produced samples that varied in
their representativeness of the general population, argu-
ably a strength in that it brought data into the survey from
diversely-sourced samples [11, 12].
The new report analyses Eurolight data for indicators
of adequacy of medical care [1]. The focus is on
migraine, and the findings are depressing. Among 1175
participants in the 10 countries reporting frequent
migraine – on more than five days per month, indicating
unambiguous need for preventative medication – fewer
than 20% had seen a health-care professional (general
practitioner [GP] or specialist). In most countries, fewer
than 10% were receiving what might be considered ad-
equate acute treatment, and even smaller proportions
had the preventative medication for which they were
clearly eligible. Participants who had managed to make
contact with specialists generally received better care by
these indicators, which might be expected. Those seeing
GPs were less well served, and those entirely dependent
on self-medication – the large majority – fared poorly.
In other words, the authors conclude, in wealthy Europe,
too few people with migraine consult physicians, and
migraine-specific medications are used inadequately
even among those who do [1]. Is there hope at all for
people with headache in less well-resourced countries?
The Eurolight report comes soon after publication of
the latest (2016) Global Burden of Disease (GBD) study
[14]. “The most comprehensive worldwide observational
epidemiological study to date” [15], GBD has been per-
formed reiteratively since 1990, with estimates of health
loss due to disease a principal objective [16]. Its findings,is distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
Table 1 Top 10 level-4 causes of disability in GBD 2016
(global, both sexes, all ages)
Low back pain
Migraine
Age-related hearing loss
Iron-deficiency anaemia
Major depression
Neck pain
Other musculoskeletal disorders
Diabetes
Anxiety disorders
Falls
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for priority setting and resource-allocation, driving
service organisation and delivery to meet assessed needs.
GBD now revises its estimates annually as it continu-
ously develops and refines the methodology of disease-
burden estimation and its expression as premature
mortality (years of life lost: YLLs) and disability (years
lived with disability: YLDs). At the same time, updated
estimates take account of new epidemiological evidence
as it continues to become available.
Since migraine was first included in GBD, it has
ascended the ranks of top causes of YLDs worldwide,
from its debut at 19th in GBD 2000 [17] to seventh in
GBD 2010 [18, 19] and sixth in GBD 2013 [20, 21]. This
persistent rise is not indicative of increasing prevalence:
it follows the collection and assimilation into GBD of ever
better data as new population-based studies have slowly
filled the large knowledge gaps, which as recently as 2007
related to more than half the world’s population [22].
With better knowledge, empirical data have replacedTable 2 GBD 2016: Years lived with disability (YLDs) attributed to m
Region Gender
Global Both
M
F
North America Both
Latin America and Caribbean
Western Europe
Central and Eastern Europe and Central Asia
South Asia
SE and East Asia and Oceania
North Africa and Middle East
Sub-Saharan Africamany of the assumptions underlying the earlier GBD esti-
mates, and, as YLD calculations became prevalence-based
rather than reliant on the less-easily ascertained incidence
and duration, estimates have gained in reliability. In GBD
2015, migraine dropped back to seventh among causes of
YLDs, partly because of revised estimates for other disor-
ders, but, being notably age-related, it was third in both
males and females aged 15–49 [23].
GBD 2016 offers sobering findings for those affected
by or who care about migraine [14]. At level two of
GBD’s disease hierarchy, neurological disorders collect-
ively account for 8.6% of all YLDs in the world, and
come fourth in the disability ranking (behind mental and
substance use, “other non-communicable” and musculo-
skeletal disorders). At level three, headache disorders are
the cause of more than three quarters of all neurological
YLDs (6.5% of all YLDs), despite that neurological
disorders include epilepsy, Alzheimer disease and other
dementias, Parkinson’s disease, multiple sclerosis and
motor neuron disease. At level four, migraine now takes
second place, responsible for 5.6% of all YLDs in the
world, behind only low back pain (7.2%) (Table 1).
There is worse. In the age group 15–49 years, migraine
is the top cause of YLDs [14] (Table 2). Let us not forget
that these are the productive years, when education is
completed, families formed, children raised, careers built
and prospects for the whole remainder of life estab-
lished. Whatever impact migraine-attributed disability
may have more generally, during these years it is greatly
magnified.
There is a ready explanation for the apparently steep
rise in migraine since GBD 2015, conducted a year
earlier: it lies with MOH. GBD 2015 regarded MOH as a
separate disease [23]. While MOH is relatively uncom-
mon (prevalence estimates vary around the world butigraine by gender, age and region (from [14])
Age range (years) % of total YLDs
(95% CI)
Rank
All
15–49
5.6 (4.0–7.2)
8.2 (6.0–10.6)
2
1
All
15–49
4.3 (3.1–5.5)
6.4 (4.6–8.2)
3
2
All
15–49
6.8 (4.9–8.8)
9.8 (7.1–12.7)
2
1
All 4.8 (3.5–6.1) 5
6.7 (4.9–8.6) 2
6.2 (4.5–7.9) 2
6.0 (4.4–7.7) 3
6.5 (4.6–8.5) 2
4.6 (3.3–6.0) 4
6.7 (5.0–8.6) 2
4.6 (3.2–6.1) 3
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disabling, by definition characterised by headache on 15
or more days per month [26]. GBD 2015 placed it 18th
among the causes of YLDs [23]. Nosologically, MOH is
undoubtedly a distinct disease [26], but aetiologically it
is a complication arising from mistreatment of other
headache disorders, principally migraine and to a
lesser extent TTH: it does not occur otherwise [26].
In GBD 2016, the decision was made that burden at-
tributed to MOH would be more correctly attributed
to the antecedent disorders, in due proportion (73.4%
to migraine, 26.6% to TTH, from a meta-analysis of
three studies [27–29]).
Not everybody may agree with this, but there is both
logic and purpose in recognising MOH as one of the
sequelae (health states) of the antecedent headache
disorder. In GBD terms, therefore, migraine is associated
with three potential health states, each occurring with
measurable probability (established in population-based
studies): the ictal state (during an attack, with its symp-
toms), the interictal state (between recurrent attacks),
and MOH. All three contribute to the disability burden
of migraine, and all three contributions should be duly
recognised. (We noted earlier that GBD does not
consider disability associated with the interictal state of
headache disorders [21], although significant interictal
burden is reported by many people with migraine [30]).
From GBD 2016 it is more evident than ever that
headache disorders have a very large detrimental effect
on public health. Table 2 shows that migraine is a major
contributor to disability throughout the world, in both
high- and low-income countries [14]. It is worth noting
that, of the 21 regions into which GBD divides the
world, five are still without any data on headache and
more have only scarce data. Furthermore, most data are
from adults, with relatively few studies reporting on chil-
dren and adolescents. Nevertheless, headache disorders
are, manifestly, an egregious cause of health loss. Why,
then, when efficacious and cost-effective treatments exist
[31, 32], do health services almost everywhere leave
them side-lined [9, 10, 33]? Will health politicians finally
take notice, now that migraine is top of the heap?
Looking forward, and not to end on an impliedly
negative note, we remind researchers that further
population-based studies are needed to fill the remaining
knowledge gaps. Quality in these is all-important:
published methodological guidelines [34] and instru-
ments [13] are available, and surveys should follow
and adopt these. Ultimately, if studies contributing to
GBD are standardized, future iterations of GBD may
not only show the relative importance of headache in
global public health but also monitor the benefits of
improvements in headache care, new treatments and
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